1. TELLOMAK: T‐CELL LYMPHOMA ANTI‐KIR3DL2 THERAPY: AN OPEN LABEL, MULTI‐COHORT, MULTI‐CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T‐CELL LYMPHOMA. (12th June 2019) Authors: Porcu, P.; Kim, Y.; Zinzani, P.; Sicard, H.; Azim, H.A.; Bagot, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies. (September 2015) Authors: Lambertini, M.; Ceppi, M.; Poggio, F.; Peccatori, F.A.; Azim, H.A.; Ugolini, D.; Pronzato, P.; Loibl, S.; Moore, H.C.F.; Partridge, A.H.; Del Mastro, L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses. (September 2015) Authors: Jung, K.H.; Ataseven, B.; Verrill, M.; De Laurentiis, M.; Azim, H.A.; Pivot, X.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Gligorov, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial. (April 2021) Authors: Gligorov, J.; Pivot, X.; Ataseven, B.; De Laurentiis, M.; Llombart, A.; Jung, K.H.; Manikhas, A.; Azim, H.A.; Alexandrou, A.; Gupta, K.; Herraez-Baranda, L.; Tosti, N.; Restuccia, E. Journal: Breast Issue: Volume 56(2021)Supplement 1 Page Start: S21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical utility of genomic tests in young women with breast cancer. (October 2018) Authors: Azim, H.A. Journal: Breast Issue: Volume 41(2018)Supplement 1 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer. (March 2015) Authors: Gligorov, J.; De Laurentiis, M.; Verrill, M.; Jung, K.H.; Azim, H.A.; Ataseven, B.; Al-Sakaff, N.; Heinzmann, D.; Shing, M.; Pivot, X. Journal: Breast Issue: Volume 24(2015)Supplement 1 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy issues in young breast cancer patients. (April 2018) Authors: Lambertini, M.; Di Maio, M.; Pagani, O.; Curigliano, G.; Poggio, F.; Del Mastro, L.; Paluch-Shimon, S.; Loibl, S.; Partridge, A.H.; Azim, H.A.; Demeestere, I.; Peccatori, F.A. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. (January 2018) Authors: Di Cosimo, S.; Campbell, C.; Azim, H.A.; Galli, G.; Bregni, G.; Curigliano, G.; Criscitiello, C.; Izquierdo, M.; de la Pena, L.; Fumagalli, D.; Fein, L.; Vinholes, J.; Ng, W.M.J.; Colleoni, M.; Ferro, A.; Naume, B.J.; Patel, A.; Huober, J.; Piccart-Gebhart, M.J.; Baselga, J. Journal: European journal of cancer Issue: Volume 89(2018) Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. (September 2017) Authors: Gligorov, J.; Ataseven, B.; Verrill, M.; De Laurentiis, M.; Jung, K.H.; Azim, H.A.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Pivot, X. Journal: European journal of cancer Issue: Volume 82(2017) Page Start: 237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗